New Drug Product Slideshows

Ibrance

In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease.

Saxenda

Adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia).

Opdivo

Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.

Movantik

Opioid-induced constipation in adults with chronic non-cancer pain.

Glyxambi

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.

Lenvima

Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Savaysa

To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant.

Belsomra

Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

New Products

CRESEMBA

  • 5/24/2015
  • Astellas Pharma US, Inc.
  • Isavuconazonium sulfate 186mg capsules; and 372mg/vial lyophilized powder for IV injection after reconstitution; preservative-free.
  • Invasive aspergillosis. Invasive mucormycosis.
IBRANCE

IBRANCE

  • 5/17/2015
  • Pfizer Inc.
  • Palbociclib 75mg, 100mg, 125mg; capsules.
  • In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease.
SAXENDA

SAXENDA

  • 5/10/2015
  • Novo Nordisk
  • Liraglutide [rDNA origin] 6mg/mL; soln for SC inj.
  • Adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 (obese), or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, T2DM, dyslipidemia). Limitations of use: not indicated for type 2 diabetes. Do not use with Victoza, other GLP-1 receptor agonists, or insulin. Effects on cardiovascular morbidity and mortality have not been established. Safety and efficacy with concomitant other weight loss products has not been established. Not studied in patients with history of pancreatitis.
OPDIVO

OPDIVO

  • 5/3/2015
  • BristolMyers Squibb
  • Nivolumab 10mg/mL; per vial; soln for IV infusion after dilution; preservative-free; contains mannitol.
  • Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
MOVANTIK

MOVANTIK

  • 4/26/2015
  • AstraZeneca Pharmaceuticals
  • Naloxegol 12.5mg, 25mg; tablets.
  • Opioid-induced constipation in adults with chronic non-cancer pain.
GLYXAMBI

GLYXAMBI

  • 4/19/2015
  • Boehringer Ingelheim and Lilly
  • Empagliflozin, linagliptin; 10mg/5mg, 25mg/5mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
LENVIMA

LENVIMA

  • 4/12/2015
  • Eisai Pharmaceuticals
  • Lenvatinib 4mg, 10mg; capsules.
  • Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

SAVAYSA

  • 4/5/2015
  • Daiichi Sankyo
  • Edoxaban 15mg, 30mg, 60mg; tablets.
  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant. Limitations of use: not for use in NVAF patients with CrCl >95mL/min.
BELSOMRA

BELSOMRA

  • 3/29/2015
  • Merck Co., Inc.
  • Suvorexant 5mg, 10mg, 15mg, 20mg; tablets.
  • Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
RAPIVAB

RAPIVAB

  • 3/22/2015
  • BioCryst Pharmaceuticals, Inc.
  • Peramivir 10mg/mL; per vial; solution for IV injection after dilution; preservative-free.
  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for ≤2 days. Limitations of use: Efficacy based on predominantly influenza A virus infections; limited number of influenza B virus subjects enrolled. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Efficacy not established in serious influenza requiring hospitalization.
BLINCYTO

BLINCYTO

  • 3/15/2015
  • Amgen, Inc.
  • Blinatumomab 35mcg; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
  • Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
VIEKIRA PAK

VIEKIRA PAK

  • 3/8/2015
  • AbbVie
  • Ombitasvir/paritaprevir/ritonavir; 12.5mg/75mg/50mg; with dasabuvir 250mg; tablets.
  • Chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin, including those with compensated cirrhosis. Limitations of use: not for use in patients with decompensated liver disease.
XIGDUO XR

XIGDUO XR

  • 3/1/2015
  • AstraZeneca Pharmaceuticals
  • Dapagliflozin, metformin HCl ext-rel; 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ­dapagliflozin and metformin is appropriate. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis.
AKYNZEO

AKYNZEO

  • 2/22/2015
  • Eisai Pharmaceuticals
  • Netupitant, palonosetron (as HCl) 300mg/0.5mg; hard gelatin capsules.
  • Prevention of acute and delayed nausea and vomiting due to initial and repeat courses of chemotherapy, including highly emetogenic chemotherapy.
LYNPARZA

LYNPARZA

  • 2/15/2015
  • AstraZeneca Pharmaceuticals
  • Olaparib 50mg; capsules.
  • Monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with ≥3 prior lines of chemotherapy.
HARVONI

HARVONI

  • 2/8/2015
  • Gilead Sciences, Inc.
  • Ledipasvir, sofosbuvir 90mg/400mg; tablets.
  • Chronic hepatitis C (CHC) genotype 1 infection.
HYSINGLA ER

HYSINGLA ER

  • 2/1/2015
  • Purdue Pharma L.P.
  • Hydrocodone bitartrate 20mg, 30mg, 40mg, 60mg, 80mg, 100mg, 120mg; extended release tablets.
  • Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of use: reserve for use in patients for whom alternative treatment options (eg, non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or inadequate to manage pain. Not indicated as an as-needed (prn) analgesic.
DUOPA

DUOPA

  • 1/25/2015
  • AbbVie
  • Carbidopa 4.63mg (as 5mg of monohydrate), levodopa 20mg; per mL; enteral susp; use with CADD-Legacy 1400 pump.
  • Treatment of motor fluctuations in advanced Parkinson’s disease.
OFEV

OFEV

ESBRIET

ESBRIET

  • 1/11/2015
  • InterMune
  • Pirfenidone 267mg; hard gelatin capsules.
  • Treatment of idiopathic pulmonary fibrosis (IPF).